慢性阻塞性肺疾病患者血浆IL-12的变化及吸入糖皮质激素对其的影响

Association of interleukin 12 with chronic obstructive pulmonary disease and the influence of glucocorticoids

目的:探讨慢性阻塞性肺疾病(COPD)患者血浆白细胞介素-12(IL-12)的变化和雾化吸入糖皮质激素治疗对其的影响。方法:采用ELISA法分别检测114例COPD患者不同分期、分度及糖皮质激素治疗后血浆IL-12的浓度,以30例健康正常人血浆IL-12的浓度为对照。结果:COPD患者血浆IL-12的浓度显著低于健康对照组(P<0.05),且急性加重期显著低于稳定期(P<0.05)。在68例急性加重期COPD患者中,轻、中、重度、极重度患者其血浆IL-12浓度相互间比较,差异均有统计学意义(P<0.05)。各30例COPD急性加重期和稳定期患者,经吸入舒利迭干粉激素治疗1个月后,血浆IL-12浓度均较治疗前明显升高(P<0.05)。结论:IL-12参与COPD的病理生理过程,并可作为判断COPD患者病变严重程度和疗效观察的指标。

Objective To investigate the change of IL-12 in the patients with chronic obstructive pulmonary disease （COPD） and the influence of glucocorticoids. Methods The plasm concentrations of IL-12 were analyzed in 114 patients with COPD by ELISA, and at the same time, 30 healthy cases were used as healthy control group. Results The plasma concentrations of IL-12 （pg/mL）in the COPD group were significantly lower than healthy controls（P 〈 0.05）. The concentration of COPD cases at acute exacerbation were significantly lower than the cases at stable stage （P 〈 0.05）. Among 68 cases of COPD patiens which were at acute exacerbation degree, the concentrations of IL-12 were significantly different （P 〈 0.05） at light degree patients, middle degree patients, severe degree patients and extreme severe degree patientswere. After 1 month therapy with inhalation of salmeterol fluticasone propionate, the concentration of IL-12 increased significantly compared with the level before treatment in both acute exacerbation group and stable group. Conclusion IL-12 participates in pathological and physiological process of COPD, and is a valuable index for judging severity of disease and therapeutic effect.